News By Tag
News By Location
Adtec Europe Ltd introduces new Actinic Keratoses Clinical Trial Results at the EADV 2018 conference
By: Adtec Healthcare Ltd
Actinic Keratoses (AK) represent the most common skin malignancy worldwide and are considered the earliest stage of squamous cell carcinoma (SCC). Importantly, up to 20% of AK transform into invasive SCC within 10-25 years.
Conventional treatments for AK and field cancerization bear significant side effects and/or are restricted to small skin areas. Thus, there is a continuing need for effective as well as non-toxic lesion and field-directed therapies for AK.
Results to be presented include data from 34 study subjects. After the final treatment, the total number of AK within the CAP-treated areas was reduced on average by 45% versus 22% within the diclofenac-treated areas. Similarly, the surface area affected by AK decreased by 47% (CAP) as compared to 32%(diclofenac)
The conclusions are that CAP is a safe as well as effective tool for the treatment of AK and field cancerization. It might be especially beneficial for patients in whom non-toxic treatment options are preferable, such as immunosuppressed individuals. The skin rejuvenating effects of CAP observed in the trial deserve further exploration.
Adtec's SteriPlas plasma medical device covers a treatment area of 12cm2 in 2 minutes. Gas Plasma has proven clinical efficacy in the management of wound and surgical site infections. The treatment is painless with no side effects or adverse events reported over 10 years of use.